Cannabis: A Clue or a Distraction in the Search for ‘Causes’ of Psychosis?

  • John McGrathEmail author
  • Louisa Degenhardt


Has cannabis been a distraction for the process of finding causes for schizophrenia or has it been a useful clue along the path to discovery? Good science is all about looking for clues, going down various pathways and then backing out if we come to a dead end. Sometimes we realize we have taken a wrong path in time to change directions quickly. Often it takes decades before we learn of our mistakes. However, it is important to note that regardless of what future researchers think about cannabis as a risk factor for psychosis, setting up and rejecting hypotheses is a defining feature of the scientific process. Rejecting a hypothesis is not an occasion for derision or hubristic scorn.


Psychotic Symptom Psychotic Disorder Cannabis User Psychotic Experience Comparative Risk Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Andreasson S, Allebeck P, Engstrom A, Rydberg U. 1987. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2(8574): 1483–6.CrossRefPubMedGoogle Scholar
  2. Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. 2003. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry 183: 427–35; discussion 436.CrossRefPubMedGoogle Scholar
  3. Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. 2004. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 184: 526–33.CrossRefPubMedGoogle Scholar
  4. Anthony JC, Degenhardt L. 2007. Projecting the impact of changes in cannabis use upon schizophrenia in England and Wales: the role of assumptions and balance in framing an evidence-based cannabis policy. Addiction 102(4): 515–6; discussion 516–8.CrossRefPubMedGoogle Scholar
  5. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. 2002. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325(7374): 1212–3.CrossRefPubMedGoogle Scholar
  6. Arseneault L, Cannon M, Witton J, Murray RM. 2004. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184. 110–7.CrossRefPubMedGoogle Scholar
  7. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. 2007. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192(3): 325–36.CrossRefGoogle Scholar
  8. Calabria B, Degenhardt L, Mclaren J, Nelson P, Roberts A, Sigmundsdottir L, Callaghan B, Baxter A, Whiteford HA. 2008. Summary of data collected and decision rules used in making regional and global estimates of cannabis dependence (available at
  9. Caspi A, Moffitt TE, Cannon M, Mcclay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A and others. 2005. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol Psychiatry 57(10): 1117–27.CrossRefPubMedGoogle Scholar
  10. Davey Smith G, Ebrahim S. 2001. Epidemiology – is it time to call it a day? Int J Epidemiol 30(1): 1–11.CrossRefPubMedGoogle Scholar
  11. Degenhardt L. 2003. The link between cannabis use and psychosis: furthering the debate. Psychol Med 33(1): 3–6.CrossRefPubMedGoogle Scholar
  12. Degenhardt L, Hall W. 2006. Is cannabis use a contributory cause of psychosis? Can J Psychiatry 51(9): 556–65.PubMedGoogle Scholar
  13. Degenhardt L, Hall W, Lynskey M, Mclaren J, Calabria B. 2008. Cannabis use as a risk factor for mental disorders. Global Burden of Disease Mental Disorders and Illicit Drug Use Expert group, Illicit drugs discussion paper No. 2.Google Scholar
  14. Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, Mckay D. 2007. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 37(7): 927–34.CrossRefPubMedGoogle Scholar
  15. Eaton WW, Romanoski A, Anthony JC, Nestadt G. 1991. Screening for psychosis in the general population with a self-report interview. J Nerv Ment Dis 179(11): 689–93.Google Scholar
  16. Ferdinand RF, Sondeijker F, Van Der Ende J, Selten JP, Huizink A, Verhulst FC. 2005. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100(5): 612–18.CrossRefPubMedGoogle Scholar
  17. Fergusson DM, Horwood LJ, Swain-Campbell NR. 2003. Cannabis dependence and psychotic symptoms in young people. Psychol Med 33(1): 15–21.PubMedGoogle Scholar
  18. Fergusson DM, Horwood LJ, Ridder EM. 2005. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 100(3): 354–66.CrossRefPubMedGoogle Scholar
  19. Gattaz WF, Hafner H. ed. 1999. Search for the Causes of Schizophrenia, Volume 4: Balance of the Century. Darmstadt, Springer-Verlag.Google Scholar
  20. Gorriti MA, Rodriguez DE Fonseca F, Navarro M, Palomo T. 1999. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365(2–3): 133–42.CrossRefPubMedGoogle Scholar
  21. Hall W, Degenhardt L. 2003. Medical marijuana initiatives: are they justified? How successful are they likely to be? CNS Drugs 17(10): 689–97.CrossRefPubMedGoogle Scholar
  22. Hall W, Degenhardt L. 2006. What are the policy implications of the evidence on cannabis and psychosis? Can J Psychiatry 51(9): 566–74.PubMedGoogle Scholar
  23. Hall W, Degenhardt L. 2008. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 7(2): 68–71.PubMedGoogle Scholar
  24. Hall W, Degenhardt L, Teesson M. 2004. Cannabis use and psychotic disorders: an update. Drug Alcohol Rev 23(4): 433–43.CrossRefPubMedGoogle Scholar
  25. Hanssen M, Bak M, Bijl R, Vollebergh W, Van Os J. 2005. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol 44(Pt 2): 181–91.CrossRefPubMedGoogle Scholar
  26. Henquet C, Murray R, Linszen D, Van Os J. 2005a. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31(3): 608–12.Google Scholar
  27. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, Van Os J. 2005b. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330(7481): 11.Google Scholar
  28. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, Van Os J. 2006. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31(12): 2748–57.CrossRefPubMedGoogle Scholar
  29. Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB. 2007. Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction 102(4): 597–606.CrossRefPubMedGoogle Scholar
  30. Hill AB. 1965. The environment and disease: association or causation? Proc R Soc Med 58: 295–300.PubMedGoogle Scholar
  31. Krabbendam L, Myin-Germeys I, De Graaf R, Vollebergh W, Nolen WA, Iedema J, Van Os J. 2004. Dimensions of depression, mania and psychosis in the general population. Psychol Med 34(7): 1177–86.CrossRefPubMedGoogle Scholar
  32. Linszen DH, Dingemans PM, Lenior ME. 1994. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51(4): 273–9.PubMedGoogle Scholar
  33. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G. 2004. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 363(9421): 1579–88.CrossRefPubMedGoogle Scholar
  34. Macleod J, Davey Smith G, Hickman M, Egger M. 2007. Cannabis and psychosis. Lancet 370(9598): 1539; author reply 1539–40.CrossRefPubMedGoogle Scholar
  35. McGrath JJ. 2005. Myths and plain truths about schizophrenia epidemiology – the NAPE lecture 2004. Acta Psychiatr Scand 111(1): 4–11.CrossRefPubMedGoogle Scholar
  36. Moon RY, Horne RS, Hauck FR. 2007. Sudden infant death syndrome. Lancet 370(9598): 1578–87.CrossRefPubMedGoogle Scholar
  37. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370(9584): 319–28.CrossRefPubMedGoogle Scholar
  38. Murray CJ, Lopez AD. 1996. The Global Burden of Disease. Boston, Harvard School of Public Health.Google Scholar
  39. Murray CJ, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, Salomon JA, Michaud CM, Walker N, Vos T. 2007a. Global burden of disease 2005: call for collaborators. Lancet 370(9582): 109–10.Google Scholar
  40. Murray RM, Morrison PD, Henquet C, Di Forti M. 2007b. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8(11): 885–95.Google Scholar
  41. Perkonigg A, Goodwin RD, Behrendt S, Beesdo K, Lieb R, Wittchen HU. 2008. Cannabis use – do we have solutions? A reply to Macleod. Addiction 103(9): 1575.CrossRefPubMedGoogle Scholar
  42. Rothman KJ, Greenland S. 2005. Causation and causal inference in epidemiology. Am J Public Health 95(Suppl 1): S144–50.CrossRefPubMedGoogle Scholar
  43. Saha S, Barendregt JJ, Vos T, Whiteford H, McGrath J. 2008. Modelling disease frequency measures in schizophrenia epidemiology. Schizophr Res 104(1–3): 246–54.CrossRefPubMedGoogle Scholar
  44. Scott EK, Mason L, Arrenberg AB, Ziv L, Gosse NJ, Xiao T, CHI NC, Asakawa K, Kawakami K, Baier H. 2007a. Targeting neural circuitry in zebrafish using GAL4 enhancer trapping. Nat Methods 4(4): 323–6.Google Scholar
  45. Scott J, Chant D, Andrews G, Martin G, McGrath J. 2007b. Association between trauma exposure and delusional experiences in a large community-based sample. Br J Psychiatry 190: 339–43.Google Scholar
  46. Semple DM, Mcintosh AM, Lawrie SM. 2005. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19(2): 187–94.CrossRefPubMedGoogle Scholar
  47. Smith GD. 2001. Reflections on the limitations to epidemiology. J Clin Epidemiol 54(4): 325–31.CrossRefPubMedGoogle Scholar
  48. Smith GD, Ebrahim S. 2004. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 33(1): 30–42.CrossRefPubMedGoogle Scholar
  49. Sullivan PF. 2008. The dice are rolling for schizophrenia genetics. Psychol Med: 1–4.Google Scholar
  50. Susser M. 1991. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 133(7): 635–48.PubMedGoogle Scholar
  51. Swinderen B. 2005. The remote roots of consciousness in fruit-fly selective attention? Bioessays 27(3): 321–30.CrossRefPubMedGoogle Scholar
  52. Tien AY, Anthony JC. 1990. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 178(8): 473–80.PubMedGoogle Scholar
  53. Van Os J, Hanssen M, Bijl RV, Ravelli A. 2000. Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res 45(1–2): 11–20.PubMedGoogle Scholar
  54. Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. 2002. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156(4): 319–27.CrossRefPubMedGoogle Scholar
  55. Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. 2008. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med: 1–17.Google Scholar
  56. Van Swinderen B. 2007. Attention-like processes in Drosophila require short-term memory genes. Science 315(5818): 1590–3.CrossRefPubMedGoogle Scholar
  57. van Winkel R, Henquet C, Rosa A, Papiol S, Fananás L, De Hert M, Peuskens J, van Os J, Myin-Germeys I. 2008. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B(1): 10–17.Google Scholar
  58. Vigano D, Guidali C, Petrosino S, Realini N, Rubino T, Di Marzo V, Parolaro D. 2008. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol: 1–16.Google Scholar
  59. Wiles NJ, Zammit S, Bebbington P, Singleton N, Meltzer H, Lewis G. 2006. Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry 188: 519–26.CrossRefPubMedGoogle Scholar
  60. Witton J, Arseneault L, Cannon M, Murray R. 2004. Cannabis as a causal factor for psychosis – a review of the evidence. In: Gattaz WF, Hafner H (ed.) Search for the Causes of Schizophrenia. Darmstadt, Steinkopff-Verlag, pp. 133–49.Google Scholar
  61. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. 2002. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325(7374): 1199.CrossRefPubMedGoogle Scholar
  62. Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. 2008. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 193(5): 357–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Queensland Centre for Mental Health ResearchThe Park Centre for Mental HealthWacolAustralia
  2. 2.National Drug and Alcohol Research CentreUniversity of New South WalesSydneyAustralia

Personalised recommendations